Company intelligence / Profile preview
Shennon Biotechnologies
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
Overview
Shennon Biotechnologies has developed a proprietary single-cell platform that enables rapid, high-throughput functional profiling of millions of immune cells to identify rare antigen-specific T or B cells. This technology aims to accelerate the development of more effective immunotherapies against solid tumors by finding novel targets that are difficult to discover using conventional methods. The company has demonstrated proof-of-concept by identifying rare functionally activated T cells from patient samples in collaboration with multiple clinical centers.
- Therapeutic areas
- Oncology
- Modalities
- T cell therapies (TCR-T)T cell engagersAntibody discovery (potentially)Cell therapy platforms
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Shennon Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shennon Biotechnologies.